Kevin Outterson is a lawyer, a professor of law and the Austin B. Fletcher Professor Boston University School of Law (2023-present).[1] He is also the executive director[2] of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies[3] developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections.
Kevin Outterson | |
|---|---|
| Alma mater | Northwestern University University of Reading |
| Occupation | Law professor |
| Employer | Boston University School of Law |
| Known for | Health Law, Intellectual Property Law, Antibiotic Resistance |
CARB-X is funded by[4] the United States, United Kingdom, German, and Canadian governments, Wellcome, the Bill & Melinda Gates Foundation, and the Novo Nordisk Foundation. In 2022, CARB-X received a new commitment of funding[5] from BARDA and Wellcome of up to $370 million. In 2023, the German and UK governments renewed funding to CARB-X, committing an additional €41 million and £24 million; the government of Canada committed CAD$6.3 million over two years; and The Novo Nordisk Foundation committed USD$25 million over three years.
The G7 Health Ministers have cited CARB-X[6] among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections. In May 2023, the global threat of Antimicrobial Resistance and the importance off supporting CARB-X as a global push incentive that coordinates and accelerates much-needed antibacterial innovation was featured in G7 Hiroshima Leaders’ Communiqué[7] and the G7 Nagasaki Health Ministers’ Communiqué.[8] The same year, G20 Health Ministers cited CARB-X as playing a critical role in accelerating antimicrobial R&D and access.[9] In May 2024, the Antimicrobial Resistance (AMR) Multi-Stakeholder Partnership Platform issued a call for actionable steps to address the rising threat of AMR ahead of the United Nations General Assembly High-Level Meeting on AMR in September 2024. The call recommended increasing public investment in push incentives to catalyze global antimicrobial R&D efforts and cited CARB-X as a push mechanism that should be mobilized due to CARB-X’s critical role in supporting the discovery and development or new antimicrobials.[10]
Outterson's research focuses primarily on the law and economics of antibiotic resistance–including push and pull incentives–health law, intellectual property, and global access to medicine.[11]
Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures.[12]
He is co-director of the health law program at Boston University School of Law (2007–present) and associate fellow at the Royal Institute of International Affairs at Chatham House,[13] London (2014–present). He served on the Board of the American Society of Law, Medicine & Ethics, and serves as faculty editor to the American Journal of Law & Medicine (2007–present). He is past editor-in-chief of the Journal of Law, Medicine & Ethics (2010–2016).[11]
References
edit- ^ "Kevin Outterson | School of Law". www.bu.edu. Retrieved 2022-08-24.
- ^ "KEVIN OUTTERSON, ESQ". Carb-X. Retrieved 2022-08-24.
- ^ "Overview". Carb-X. Retrieved 2022-08-24.
- ^ "Funding Partners". Carb-X. Retrieved 2022-08-24.
- ^ "CARB-X". May 19, 2022.
- ^ "G7 Health Ministers' Communiqué" (PDF). G7 Germany. May 20, 2022.
- ^ G7 Hiroshima Leaders’ Communiqué (PDF). G7 Japan. May 20, 2023.
- ^ G7 Nagasaki Health Ministers’ Communiqué (PDF). G7 Japan. May 13, 2023.
- ^ G20 Health Ministers' Outcome Document (PDF). G20 India. August 19, 2023.
- ^ Call for actionable steps in response to the rising threat of antimicrobial resistance (AMR) Antimicrobial Resistance (AMR) Multi-Stakeholder Partnership Platform. May 2024.
- ^ a b "Kevin Outterson | School of Law". www.bu.edu. Retrieved 12 May 2020.
- ^ "Boston University" (PDF). July 2015.
- ^ "Kevin Outterson". Chatham House – International Affairs Think Tank. Retrieved 2022-08-24.
External links
edit- Kevin Outterson publications indexed by Google Scholar
- "Racing the clock to stop drug-resistant superbugs" The Boston Globe by Maryn McKenna
- "Accelerating global innovation to address antibacterial resistance: introducing CARB-X" Nature Reviews Drug Discovery
- "Can we prevent antibiotic resistance?" The Brink by Robin Berghaus
- "Antibiotic-resistant infections could dwarf the COVID-19 pandemic" The Boston Globe by Kevin Outterson and Henry Skinner
- "A better way to fund the fight against superbugs" Bloomberg by James Paton
- "The battle against bugs" Boston Business Journal by Rowan Walrath
- "Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)" Progress, Potential, and Possibilities hosted by Ira Pastor
- "The Global Burden of AMR" Infectious Conversations hosted by Candace DeMatteis, Partnership to Fight Infectious Disease
- "Antibiotic Resistance: How CARB-X Helps New Companies Get a Running Start" The State of Health with Gunnar Esiason
  | This American law–related biographical article is a stub. You can help Wikipedia by expanding it. |